Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~To be eligible for inclusion into the Double-blind Phase of the study, a patient must meet the following criteria:~* Has end-stage renal disease (ESRD) and has been on hemodialysis 3 times per week for at least 3 months prior to the start of screening;~* Has at least 2 single-pool Kt/V measurements ≥1.2, or at least 2 urea reduction ratio measurements ≥65%, or 1 single pool Kt/V measurement ≥1.2 and 1 urea reduction ratio measurement ≥65% on different dialysis days during the 3 months period prior to screening;~* Prior to randomization:~  * Has completed Worst Itching Intensity NRS worksheets up to 8 days prior to 1st dose;~ * Has a mean baseline Worst Itching Intensity NRS indicative of moderate to severe uremic pruritus.~* To be eligible for inclusion into the Open-label Extension Phase of the study, each patient will have to fulfill the additional key following criteria at the time of entry into the Open-label Extension Phase:~  * Has received at least 30 doses of the planned 36 doses of study drug during the Double-blind Phase of this study;~ * Continues to meet inclusion criteria.~Key Exclusion Criteria:~A patient will be excluded from the Double-blind Phase of the study if any of the following criteria are met:~* Known noncompliance with dialysis treatment that in the opinion of the investigator would impede completion or validity of the study;~* Scheduled to receive a kidney transplant during the study;~* New or change of treatment received for itch including antihistamines and corticosteroids (oral, IV, or topical) within 14 days prior to screening;~* Received another investigational drug within 30 days prior to the start of screening or is planning to participate in another clinical study while enrolled in this study;~* Has pruritus only during the dialysis session (by patient report);~* Is receiving ongoing ultraviolet B and anticipates receiving such treatment during the study;~* Participated in a previous clinical study with CR845.~* A patient will be excluded from the Open-label Extension Phase of the study if any of the additional key following criteria are met at the time of entry into the Open-label Extension Phase:~  * Completed the Double-blind Phase of this study but exhibited adverse events during the course of the Treatment Period that may preclude continued exposure to the study drug;~ * Was noncompliant with protocol procedures during the Double-blind Phase of this study which is indicative of an inability to follow protocol procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CR845 0.5mcg/kg (Type: ACTIVE_COMPARATOR): IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
- Placebo (Type: PLACEBO_COMPARATOR): IV Placebo administered after each dialysis session (3 times/week)

Based on this trial design, predict the completion outcome and termination type (if applicable).